Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view

Affiliations

¹ Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
² Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
³ Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Erlangen, Germany.
⁴ Department of Urology, UZ Leuven, Leuven, Belgium.
⁵ Organ Systems, KU Leuven, Leuven, Belgium.
⁶ Department of Pathology, AZ Klina, Brasschaat, Belgium.
⁷ Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
⁸ Department of Pathology and Surgery, Cordoba University, Faculty of Medicine, Cordoba, Spain.

Editorial

Alessia Cimadamore et al. Expert Opin Biol Ther. 2020 Jun.

. 2020 Jun;20(6):539-544.

doi: 10.1080/14712598.2020.1733965. Epub 2020 Feb 25.

¹ Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
² Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
³ Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Erlangen, Germany.
⁴ Department of Urology, UZ Leuven, Leuven, Belgium.
⁵ Organ Systems, KU Leuven, Leuven, Belgium.
⁶ Department of Pathology, AZ Klina, Brasschaat, Belgium.
⁷ Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
⁸ Department of Pathology and Surgery, Cordoba University, Faculty of Medicine, Cordoba, Spain.

No abstract available

Keywords: Bladder cancer; PD-L1; PD-L1 testing; immunohistochemistry; immunotherapy.

Comment on

An update on immunotherapy options for urothelial cancer.
Bilgin B, Sendur MAN, Hizal M, Yalçın B. Bilgin B, et al. Expert Opin Biol Ther. 2019 Dec;19(12):1265-1274. doi: 10.1080/14712598.2019.1667975. Epub 2019 Sep 17. Expert Opin Biol Ther. 2019. PMID: 31518156 Review.